Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS
The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.
Siponimod Improves Cognitive Processing Speed, Opioid Use for Migraine in Emergency Departments, Reduced Stroke Admissions During Pandemic
Neurology News Network for the week ending February 27, 2021.
Natalizumab Infusion Reports Strong Safety Profile, Rarely Causes Adverse Events in Relapsing MS
Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.
Social Activity Participation Impacted by Invisible Symptoms of MS
Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.
NeurologyLive Friday 5 — February 26, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.
Instrumented Postural Sway Test Differentiates Fallers From Non-Fallers in MS
Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.
Investigating TNFα Inhibition and CNS Demyelination: Spencer Hutto, MD
The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.
New Studies Evaluating Anakinra and Tolebrutinib on Paramagnetic Rim Lesions in MS
The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.
Episode 30: Cognitive Behavioral Therapy for Insomnia
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Martin, PhD.
Frenkel Coordination Exercises Demonstrate Reliability, Fatigue Benefits in Multiple Sclerosis
The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.
Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
Sarepta’s Casimersen Approved for DMD Amenable to Exon 45 Skipping
The antisense oligonucleotide casimersen will be branded as Amondys 45 and is currently being assessed in the ESSENCE phase 3 clinical trial (NCT02500381).
Cladribine Demonstrates CD19+ B and CD4+ T Lymphocyte Impact Regardless of Age
The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.
Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
TNFαi-Associated CNS Demyelination Persists After Treatment Discontinuation
Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.
Tapping Into the Potential of Cell and Gene Therapy
Advancements in gene therapy approaches have opened the door for a glimpse into the future of care for a number of diseases.
Parkinson Disease Treatment Tavapadon Aims to Benefit From Unique Multitrial Designs
Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.
ACTRIMS Forum 2021: What to Expect From the Virtual Meeting
Ahead of sessions kicking off on February 25, the ACTRIMS committee offered a look into what data, plenary talks, and developments are set to be presented at the upcoming ACTRIMS Forum 2021.
Intensive Motor Arm Therapy Improves mRS Scores in Poststroke Patients
Similar proportions of both in-clinic and telemedicine patients had modified Rankin scale score improvements.
ACTRIMS Forum 2021: Pre-Conference Expert Perspective
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.
Improving Sleep Care with Integrated Sleep Centers: William Noah, MD
The director and founder of the Sleep Centers of Middle Tennessee compared the integrated care model of ISPs to the transactional model of DMEs.
NeuroVoices: Stephen Rao, PhD, and Jay Alberts, PhD, on High-Intensity Exercise in Preventing Alzheimer Disease
The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.
Aducanumab and the Alzheimer Disease Treatment Landscape
The director of Neurology and the Memory and Aging Program at Butler Hospital and principal investigator in the aducanumab clinical trial program discussed the investigational agent and the current landscape of care.
The Variability of Cerebral Palsy Care: Bhooma Aravamuthan, MD, DPhil
The assistant professor of pediatric neurology at the Washington University in St. Louis spoke to the insights of a recent survey she and colleagues conducted.
Common Migraine Interventions Ineffective in Reducing Disease Burden
A recent study investigated self-reported outcomes of preventive treatment prior to the introduction of calcitonin gene related peptide (CGRP) receptor targeting.
Emergency Room Opioid Use for Migraine Linked to Future Health Costs
Factors such as previous emergency department visits, hypertension, and tobacco use disorder were related to future migraine-related emergency department visits.
Comparing Poststroke Trials of Brian Implants: Mijail Serruya, MD, PhD
The assistant professor of neurology at Thomas Jefferson University gave background on what other studies have observed brain implants for poststroke patients and how they differ from his work.
Expert Perspectives on the Advances in the Management of Acute Migraine
A pair of migraine experts explores several topics in the acute treatment of migraine, including recent therapeutic innovations.
Siponimod Offers Benefit to Cognitive Processing Speed in SPMS
Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.
Rimegepant vs. Monoclonal Antibodies for Migraine Prevention: Richard B. Lipton, MD
The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.
